Drug Watch

Galderma launches clinical trials for nemolizumab, targeting systemic sclerosis and chronic pruritus of unknown origin, addressing critical patient needs.

The new PDUFA date is set for September 2025.

Dupilumab gains FDA approval as the first targeted therapy for bullous pemphigoid, offering hope for effective treatment and improved patient outcomes.

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

Zasocitinib emerges as a promising oral therapy for psoriasis and psoriatic arthritis, showcasing superior selectivity and safety compared to traditional JAK inhibitors.

Sagimet Biosciences reveals denifanstat's promising phase 3 results, offering a novel oral treatment for moderate to severe acne with significant efficacy.

FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.

Quoin Pharmaceuticals advances QRX003 for Netherton Syndrome, receiving FDA clearance for a pivotal trial to assess its effectiveness and safety.

Accropeutics reveals promising Phase 2 trial results for AC-201, a selective TYK2/JAK1 inhibitor, showing significant efficacy in treating plaque psoriasis.

The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.

Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.

The FDA approved pz-cel, a groundbreaking gene therapy for recessive dystrophic epidermolysis bullosa, transforming treatment options for patients.

Dupilumab becomes the first targeted therapy approved for chronic spontaneous urticaria in more than a decade.

Having multiple therapeutic options would allow clinicians to tailor treatment and offer hope to patients who don't respond initially.

While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.

Exclusive Q1 Report: A comprehensive look at the latest FDA approvals and pipeline developments in dermatology from the first quarter of 2025.

The novel treatments will be for patients with orphan conditions like Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and palmoplantar keratoderma.

A pilot study revealed that mitochondrial complex I-blocking drugs, like metformin and berberine, improved TSW symptoms in most participants.

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

Medicus’ previous phase 1 study confirmed D-MNA’s safety, with some participants achieving complete BCC clearance.

The company showcased advancements in tirbanibulin and its early-stage antibody LAD191.

Published in JID, the study analyzes data from the FDA’s FAERS database to examine cases of neoplasms—including skin and breast cancers—potentially associated with benzoyl peroxide use.

The findings of the MVOR-1 and MVOR-2 studies are published in JAMA Dermatology, supporting the rosacea drug’s recent FDA approval.

After just 2 weeks of twice-daily use, a pediatric patient saw visually improved skin with no adverse events.

DELTA China follows the success of European and Canadian trials, reinforcing delgocitinib’s potential as a global treatment for CHE.

A PDUFA target action date has been set for October 13, 2025.

Snail slime contains bioactive compounds that promote skin healing, hydration, and regeneration.

The POETYK PSO LTE trial found deucravacitinib effective in sustaining PASI 75 and PASI 90 responses.

Alphyn’s therapy uniquely treats both the immune system and bacterial components of atopic dermatitis.